FormWeb • conjugated estrogens IV

IHS FormWeb

Approved Formulary

Search by class Show Therapeutic Classes

Staff Telephone Numbers

Add Formweb to your mobile device

Android iOS

Search results for:

conjugated estrogens IV

conjugated estrogens IV

Brand names: Premarin Intravenous

Form	Strength
POWDER FOR INJECTION, INJECTABLE	25 mg

Display Estrogens, Bone Resorption Inhibitors Class: 681604, 922400

Medication comments:

Refrigerator item

USP <800> Hazardous Drug Assessment of Risk (AOR)
Per policy, these drugs are exempt from USP <800> handling requirements under normal circumstances. The following outlines must be followed.
generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	Activities
estrogens, conjugated (Premarin) IV [n/a]		Stock @ IDBH? N NIOSH Table 1^A↑
Pharmacy: Receiving / Storage / Preparation Exposure Risk: low	• Handling/preparation PPE Requirements: Single CX glove, gown
	• Receiving from Distributor: Standard
	• Pharmacy Storage Area: IV (fridge)
	• Packaging/Reconstitution Location: n/a
	• Compounding (Non-Sterile/Sterile) Location: Positive pressure room
	• Omnicell Load: No
Transport	• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration Exposure Risk: low	• Handling/administration PPE Requirements: Single pair of CX approved gloves Wash hands after handling
	• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
	• Signage on Patient Door Required: No
	• Manipulation of Dosage Form: n/a
	• Special Manipulation for Administration: n/a
Disposal / Spills	• Disposal of Drug Waste: Full- black bin Trace/packaging- yellow bin
	• Disposol of Used PPE: trash bin (inside plastic bag)
	• Spill management: Wear CX gloves items used to clean up spill should be placed in a sealed bag and put in blue bin
NIOSH Supplemental Information: BBW for malignant neoplasms; increased risk of endometrial, ovarian and breast cancer; in laboratory studies, increased frequency of carcinomas of breast, uterus, cervix, vagina, testis, and liver; present in breast milk. Listed by NTP and IARC. Not listed by OSHA. Take up mechanically and collect in suitable container for disposal. Clean contaminated surface thoroughly.
Reason for exemption of USP<800> Containment Requirements: Pregnancy Category X. Risks are related to systemic absorption.

2023 American Geriatrics Society Beers Criteria^® for potentially inappropriate medication use in older adults.
Medication:	estrogens, conjugated (Cenestin)
Criteria 1: Potentially inappropriate medication use in older adults. (Table 2)
Drug(s)	estrogens with or without progestins (includes natural and synthetic estrogen preparations)
Rationale	Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women. For women who start HRT at age 60 and older, the risks of HRT are greater than the benefits, as HRT is linked to a higher risk of heart disease, stroke, blood clots, and dementia. Evidence indicates that vaginal estrogens for the treatment of vaginal dryness are safe and effective; women with a history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and benefits of low-dose vaginal estrogen (e.g., dosages of estradiol <25 mcg twice weekly) with their healthcare provider.
Recommendation	Do not initiate systemic estrogen (e.g., oral tablets or transdermal patches). Consider deprescribing among older women already using this medication. Vaginal cream or vaginal tablets: acceptable to use low-dose intravaginal estrogen for the management of dyspareunia, recurrent lower urinary tract infections, and other vaginal symptoms.
Quality of evidence: Oral and patch: high Vaginal cream or vaginal tablets: moderate, Strength of Recommendation: Oral and patch: strong Topical vaginal cream or tablets: weak

Criteria 2: Potentially inappropriate medication use in older adults due to drug–disease or drug–syndrome interactions that may exacerbate the disease or syndrome. (Table 3)
Drug(s) ⇆ disease or syndrome	estrogen, oral and transdermal (excludes intravaginal estrogen) ⇄ Urinary incontinence (all types) in women
Rationale	Lack of efficacy.
Recommendation	Avoid in women. See also recommendation on estrogen (Table 2)
Quality of evidence: High, Strength of Recommendation: Strong

Last updated: Sep. 19, 2025

Hazard.Drug Handling(USP 800) USP<800> Hazardous Drug / Assessment of Risk
Black Box Warnings Endometrial cancer; cardiovascular; dementia risk

UpToDate Lexidrug

Pharmacy Contact Info:

Main Inpatient Pharmacy: ext 4599, 3503
Fax: 704-878-7283

Director of Pharmacy - Randi Raynor, PharmD: ext 4501
Clinical Coordinator - Laura Rollings, PharmD: ext 4597
Pharmacy Informaticist - Stephen Pringle, PharmD: ext 7645
Pharmacy Technician Supervisor - Amy Wingler, CPhT: ext 7385
Pharmacy Automation Coordinator (Omnicell) - Melissa Fulford, CPhT: ext 3556

This site is intended for the staff of Iredell Health System. While others may view accessible pages, Iredell Health System makes no warranty, express or implied, as to the use of this information outside of Iredell Health System. The content of this policy and procedure document serves as guidance to the delivery of quality patient care. Care providers are expected to exercise critical thinking and situational awareness skills, and in specific situations to take such action as is necessary for the delivery of quality patient care.